Literature DB >> 20004980

Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists.

Matthias Jaeger1, Wulf Rossler.   

Abstract

In many countries fewer than 20% of individuals with schizophrenia receive depot antipsychotic medication. Frequently stated reasons are psychiatrist's, patient's and relative's objections to depot treatment. This is the first study that directly compares the attitudes to depot antipsychotics of psychiatrists, patients and relatives. A semi-structured questionnaire about their attitudes towards depot antipsychotics was completed by 255 participants (83 patients diagnosed with schizophrenic disorder, 81 psychiatrists in private practice and 91 relatives, not directly related to the patients). Patients were more negative towards depot injections than psychiatrists and relatives. They particularly fear to be constricted in their autonomy when treated with depot antipsychotics and that injections might be painful. About 67% of all patients in our sample did not receive information about depot antipsychotics from their psychiatrist. Less than 10% of psychiatrists offer depot treatment after a first psychotic episode. Psychiatrists use depot antipsychotics in a conservative way, although they attribute positive traits to the method. Patients' negative attitudes might relate to the low level of information. To enhance the use of depot antipsychotics, information practices of psychiatrists should be improved. Patients should be informed about different forms of treatment during early stages of the illness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004980     DOI: 10.1016/j.psychres.2008.11.003

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  39 in total

1.  A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections.

Authors:  Amlan K Das; Abid Malik; Peter M Haddad
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  Plasma levels and estimated dopamine D2 receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study.

Authors:  Saeko Ikai; Takefumi Suzuki; Masaru Mimura; Hiroyuki Uchida
Journal:  Psychopharmacology (Berl)       Date:  2016-09-08       Impact factor: 4.530

Review 3.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

4.  A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder.

Authors:  William V Bobo; Richard A Epstein; Alan Lynch; Tynya D Patton; Nicholas A Bossaller; Richard C Shelton
Journal:  Clin Neuropharmacol       Date:  2011 Nov-Dec       Impact factor: 1.592

Review 5.  Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2010-12-03       Impact factor: 9.546

Review 6.  Improving treatment adherence in your patients with schizophrenia: the STAY initiative.

Authors:  Fernando Cañas; Koksal Alptekin; Jean Michel Azorin; Vincent Dubois; Robin Emsley; Antonio G García; Philip Gorwood; Peter M Haddad; Dieter Naber; José M Olivares; Georgios Papageorgiou; Miquel Roca
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

7.  The knowledge and attitudes of psychiatrists towards antipsychotic long-acting injections in Nigeria.

Authors:  Bawo O James; Joyce O Omoaregba; Kingsley M Okonoda; Edebi U Otefe; Maxine X Patel
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

Review 8.  Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.

Authors:  Eduard Parellada; Miquel Bioque
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

9.  Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis.

Authors:  Matthias Kirschner; Anastasia Theodoridou; Paolo Fusar-Poli; Stefan Kaiser; Matthias Jäger
Journal:  Ther Adv Psychopharmacol       Date:  2013-04

10.  Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia.

Authors:  Cheng-Yi Huang; Su-Chen Fang; Yu-Hsuan Joni Shao
Journal:  JAMA Netw Open       Date:  2021-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.